×
BioNexus Gene Lab Common Stock Net 2019-2025 | BGLC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BioNexus Gene Lab common stock net from 2019 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
BioNexus Gene Lab Common Stock Net 2019-2025 | BGLC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BioNexus Gene Lab common stock net from 2019 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Danaher (DHR)
$143.6B
CVS Health (CVS)
$83.1B
Elevance Health (ELV)
$66.2B
Cencora (COR)
$55.3B
DiDi Global (DIDIY)
$26.1B
Labcorp Holdings (LH)
$22.1B
Natera (NTRA)
$20.7B
BioMerieux (BMXMF)
$17.7B
EUROFINS SCIENT (ERFSF)
$14.9B
CochLear (CHEOY)
$13.2B
ICON (ICLR)
$12.8B
Solventum (SOLV)
$12.7B
Medpace Holdings (MEDP)
$12.2B
Viatris (VTRS)
$11.4B
Revvity (RVTY)
$10.1B
Sonic Healthcare (SKHHY)
$9B
HealthEquity (HQY)
$8B
Avantor (AVTR)
$7.8B
Caris Life Sciences,�Inc (CAI)
$7.6B
Charles River Laboratories (CRL)
$7.3B
Bausch + Lomb (BLCO)
$4.8B
Sotera Health (SHC)
$4B
Amplifon S.p.A (AMFPF)
$3.9B
BrightSpring Health Services (BTSG)
$3.7B
Surgery Partners (SGRY)
$3B
GeneDx Holdings (WGS)
$3B
Alignment Healthcare (ALHC)
$2.9B
Concentras Parent (CON)
$2.8B
Organon (OGN)
$2.4B
Progyny (PGNY)
$2B